Detail of the clinical trial

Title of the trial A phase 3, multicenter, randomized, open-label, study of Azacitidine (Vidaza) versus conventional care regimens for the treatment of older subjects with newly diagnosed acute myeloid leukemia
EudraCT number 2009-012346-23
Protocol number AZA-AML-001
Sponsor Celgene Corporation, Summit, USA
Indications Hemato-oncology
Diagnosis acute myeloid leukemia
Population in clinical trial Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2010
Date of approval by Institute (SÚKL) 14.7.2010
Date of approval by EC 14.7.2010
Date of initiation CT in ČR 26.4.2011
Date of ending CT in ČR 25.3.2014
Notice
Sites Ústav hematologie a krevní transfuse, U Nemocnice, Praha 2
I. interní klinika hematoonkologie VFN a 1. LF UK, U Nemocnice, Praha 2
Interní hematoonkologická klinika, FN Brno
Hemato-onkologická klinika, FN Olomouc

‹‹ Back to list